Quote from Stocktwits:
wCVR perceived as valuable
→ shareholders want guaranteed entitlement
→ shareholders/brokers recall lent CHRS
→ available borrow declines
→ borrow rate rises
→ some shorts voluntarily cover
→ CHRS rises
→ mark-to-market pressure on remaining shorts
→ additional covering“
Quote from Stocktwits: „Most likely: Coherus wants to become a clean, pure-play oncology company before the important clinical readouts.
Also plausible: Management believes it has sufficient financing flexibility and therefore does not need to retain the legacy biosimilar economics.
Potential upside scenario: Strong October casdozokitug results lead to licensing/partnership discussions with larger pharma companies.
More speculative scenario: The corporate cleanup is partly preparing Coherus for an eventual acquisition.
The most interesting aspect for me is therefore not the CVR's potential dollar value itself. It is the timing: Coherus is cleaning up the corporate structure and refinancing shortly before what could be its most important clinical readout.“ https://stocktwits.com/Sven\_Bonn/message/662145731